Crossmark

Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study

Crossref DOI link: https://doi.org/10.1007/s40744-024-00683-0

Published Online: 2024-06-09

Published Print: 2024-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shen, Zhen-Wei

Wu, Kai-Qi

Jin, Ting-Han

Zhao, Jie

Jiang, Qi

Guo, Tong

Fang, Min

Chen, Gui-Ling https://orcid.org/0009-0004-7343-6996
License Information

Text and Data Mining valid from 2024-06-09

Version of Record valid from 2024-06-09
More Information

Article History

Received: 25 March 2024

Accepted: 21 May 2024

First Online: 9 June 2024

Declarations

:

: Zhen-Wei Shen, Kai-Qi Wu, Ting-Han Jin, Jie Zhao, Qi Jiang, Tong Guo, Min Fang, and Gui-Ling Chen have nothing to disclose.

: The protocol, informed consent, and amendments were approved by the ethical Review Committee of Shulan (Hangzhou) Hospital(2021–26). All subjects signed written informed consent forms before participating. This study was conducted in accordance with the Good Practice for Quality Management of Clinical Trials (GCP), the current Declaration of Helsinki (2013), relevant regulations, and Ethics Committee reviews.

Document is current

Any future updates will be listed below